Search for: "Insurance Companies A,B"
Results 5041 - 5060
of 8,130
Sorted by Relevance
|
Sort by Date
29 Jan 2014, 5:30 am
Robert B. [read post]
8 Jul 2014, 6:30 am
Author Michael B. [read post]
7 Nov 2013, 5:30 am
” Author Michael B. [read post]
2 Oct 2013, 6:30 am
Attorney Ronca can be reached at 631-722-2100. medsearch7@optonline.net Editor Michael B. [read post]
9 Jun 2015, 6:35 am
Author Michael B. [read post]
12 Apr 2013, 8:49 am
§ 1332(d)(2), (d)(5)(B). [read post]
16 Dec 2013, 7:13 am
Author Michael B. [read post]
29 Jan 2014, 6:30 am
Editor Michael B. [read post]
1 Mar 2010, 8:07 pm
District Court Erred in Denying Class Action Certification Motion in Class Action Alleging Violations of Hawaii’s Deceptive Practice Act because Hawaii Case Law Establishes that Individualized Reliance need not be Shown so Common Questions Predominated over Individual Questions Ninth Circuit Holds Plaintiff filed a putative class action against Midland National Life Insurance Company alleging violations of Hawaii’s Deceptive Practices Act; specifically, the class action… [read post]
1 Apr 2015, 6:30 am
Author Michael B. [read post]
18 Jul 2022, 5:27 pm
A Lawyer who should appear as a Gecko for some insurance company advertisement? [read post]
22 Oct 2013, 6:30 am
Editor Michael B. [read post]
15 Jul 2014, 6:30 am
Author Michael B. [read post]
20 Aug 2014, 6:30 am
Author Michael B. [read post]
9 Nov 2015, 8:57 am
In this case, the physician did not remember a letter from a family remember reporting abuse even though it was in the chart and he had referenced it in a letter to the insurance company. [read post]
30 Jul 2014, 6:30 am
Author Michael B. [read post]
18 Dec 2013, 6:30 am
Editor Michael B. [read post]
30 Apr 2015, 6:30 am
Author Michael B. [read post]
8 May 2013, 8:13 am
medsearch7@optonline.net Editor Michael B. [read post]
15 Nov 2022, 8:22 am
According to the Federal Register Notice, the USPTO is interested in “feedback from a broad group of stakeholders, including, but not limited to, patients and their caregivers, patient advocates, representatives from regulated industry, including companies that sell branded medicines, generics drugs and biosimilars, healthcare organizations, payors and insurers, academic institutions, public interest groups, and the general public. [read post]
